Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
29 May 2020 13:00 BST Imfinzi showed a sustained overall survival benefit in 1st-lineextensive-stage small cell lung cancer in the Phase III CASPIAN trial ASCO data show more than 10% of patients on Imfinzi plus chemotherapy had not progressed and remained on treatment at two years vs. 2.9% on chemotherapy alone Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca's Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall